title: Effects of Arsenic Trioxide on Minor Progressive High-Grade Osteosarcoma of the Extremities Metastatic to the Lung: Results of 39 Patients Treated in a Single Institution.
abstract: Patients who mildly progressed after first-line chemotherapy were administered arsenic trioxide (ATO) 5-10 mg intravenously daily. Thirty-nine patients were finally enrolled in the study, of whom 19 patients received first-line chemotherapy with ATO infusion while 20 patients did not. Progression-free survival at 4 months was 89.2 and 62.7% (p = 0.043) for the ATO group and the control group, respectively, while the 2-year overall survival was 61 and 16.4% (p = 0.032).
authors.affiliation: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Xie
authors.affiliation: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.affiliation: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Tang
authors.affiliation: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Xu
keywords: Arsenic trioxide; Osteosarcoma, minor progressive; Pulmonary metastasis